The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study to Evaluate D-1553 in Subjects With Solid Tumors
Official Title: A Phase 1/2, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects With Advanced or Metastatic Solid Tumors With KRasG12C Mutation
Study ID: NCT04585035
Brief Summary: This is a phase 1/2, open label study of D-1553 single agent and combination treatment to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with advanced or metastatic solid tumor with KRasG12C mutation.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Research Site, Fresno, California, United States
Research Site, Orange, California, United States
Research Site, San Francisco, California, United States
Research Site, Louisville, Kentucky, United States
Research Site, Detroit, Michigan, United States
Research Site, New York, New York, United States
Research Site, Portland, Oregon, United States
Research Site, Blacktown, New South Wales, Australia
Research Site, East Albury, New South Wales, Australia
Research Site, Kogarah, New South Wales, Australia
Research Site, Waratah, New South Wales, Australia
Research Site, Woodville South, South Australia, Australia
Research Site, Fitzroy, Victoria, Australia
Research Site, Frankston, Victoria, Australia
Research Site, Malvern, Victoria, Australia
Research Site, Nedlands, Western Australia, Australia
Research Site, Seogu, Busan, Korea, Republic of
Research Site, Seongnam-si, Gyeonggi-Do, Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Tainan, , Taiwan
Research Site, Taipei City, , Taiwan
Research Site, Taipei, , Taiwan
Research Site, Taoyuan City, , Taiwan